This is a single arm phase II study of docetaxel, prednisone, and sunitinib systemic therapy
followed by salvage external beam radiation therapy for men who have experienced PSA
recurrence following initial radical prostatectomy for prostate cancer. The primary aim is
the rate of progression-free survival at 2 years as measured by lack of PSA progression and
no evidence of disease. We hypothesize that this aggressive initial systemic therapy will
improve the long term remission rates for men who are undergoing salvage radiation therapy
for PSA recurrence in the absence of metastatic disease.